Search

Displaying results 3781 - 3790 of 4600 in total
  1. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.

  2. Drug

    Penimepicycline

    go.drugbank.com/drugs/DB13264
    Experimental

    It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

  3. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine.

  4. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.

  5. Drug

    Anti-SARS-CoV-2 IgY

    go.drugbank.com/drugs/DB16356
    Investigational

    From there, the chicken antibodies are harvested from the egg yolks of the eggs laid by these chickens and formulated into the nasal drops that can be administered. … [L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards

  6. Drug

    Indopan

    go.drugbank.com/drugs/DB01446
    ExperimentalIllicit

    It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

  7. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  8. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  9. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  10. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by